Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, has officially announced the launch of CARTO™ 3 System Version 8, which happens to be the latest version of its leading three-dimension (3D) heart mapping system used in cardiac ablation procedures. Under the given update, the device has been bestowed with new modules including CARTO ELEVATE™ Module and CARTOSOUND™ FAM Module, both designed to achieve efficiency, reproducibility, and accuracy for electrophysiologists performing catheter ablation procedures. Talk about these modules on a slightly deeper level, we begin from CARTOSOUNDTM FAM, where you get the first use of an artificial intelligence algorithm cleared by the FDA for intracardiac ultrasound. In practice, the stated algorithm facilitates automatic generation of the left atrial anatomy before inserting the catheter to the left atrium so to save time, while simultaneously providing a highly accurate map. Moving on to CARTO ELEVATE, this one actually packs together several new features to electrophysiologists’ needs. For starters, the module brings to the fore multipolar capabilities with the OPTRELL™ Mapping Catheter. Such capabilities, on their part, are meant for localized unipolar signals to significantly reduce far field potentials and provide a more accurate activation map. Next up, we must get into the module’s ability to recognize complex signals for efficient and reproducible identification of critical and relevant areas when diagnosing arrhythmia.
“Accuracy and precision in mapping the heart when treating cardiac arrhythmias are critical for electrophysiologists, and therefore, our patients,” said Luigi Di Biase, System Director of Electrophysiology at Montefiore-Einstein Health System and Professor of Medicine (Cardiology) at Albert Einstein College of Medicine. “The CARTO ELEVATE™ Module raises the bar for electro-anatomical mapping systems used in catheter ablation procedures. Capabilities such as Multipolar mapping make a difference for electrophysiologists in the electrophysiology lab, facilitating a reduction in far-field signal and increased focus on the electrical signals in the patient’s heart that contribute to arrhythmias.”
Hold on, there are still a few bits left to unpack, considering we haven’t touched on CARTO ELEVATE’s efficiency in the context of spotting problematic patterns. You see, owing to that, the module is able to help CARTO™ 3 System automatically track arrhythmia burden pre- and post-ablation, and therefore, birth a more informed decision of the relevant premature activation map. Rounding up highlights would be an enhanced CONFIDENSE™ Module, which is baked right into CARTO ELEVATE for the purpose of creating optimized maps with higher overall Smart Index scores. Not just that, the stated feature also goes a long way to ensure that these maps are improved on a continuous basis.
Contextualizing the importance held by such an update talks to how AFib is the most common type of cardiac arrhythmia, affecting more than 8 million people in the United States alone, and nearly 50 million people worldwide. In response to that, Biosense Webster launched its CARTO™ 3 System back in 2009. The stated system would bring a three-dimensional mapping system, which in turn, uses electromagnetic technology to generate real-time maps of a patient’s cardiac structures. More on these maps is going to reveal that they leverage 3D technology, during diagnosis and therapeutic procedures, to pinpoint the exact location and orientation of catheters in the heart
“We are pleased to announce this new version of our CARTO™ 3 System, which reflects our continued focus on harnessing the latest science and technology to advance tools for electrophysiologists to treat cardiac arrhythmias,” said Jasmina Brooks, President at Biosense Webster, Inc. “The CARTO™ 3 System has been the cornerstone of catheter ablation procedures for more than a decade, helping electrophysiologists make treatment decisions. This new version advances the CARTO™ 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilization of ultrasound technology.”
